FBRX

Forte Biosciences, Inc. (FBRX) | Rumor.io

Forte Biosciences

FBRX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,324

Bullish sentiment (50-day avg)87%

Price to earnings ratio-16.3

Market capitalization1.6B

Earnings per share-4.57

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-69.4M

Social

What share of all stock conversation is about FBRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 28

Forte Biosciences (FBRX) is being acquired by argenx for approximately $2.2 billion, or $77 per share in cash, an 86% premium over the company's average stock price since its strong rally.
The acquisition of FBRX is valued at $2.2 billion, with Forte's autoimmune candidate FB102, for vitiligo and celiac disease, being the prize.
FBRX surged 40% after the acquisition announcement, with some analysts considering the deal a strong validation of the company's pipeline potential in a hot M&A biotech environment.

Generated by AI

Sentiment

Of the messages about FBRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +13.33	83.79% +2.65
Bearish	—	—	0% -13.33	16.21% -2.65

Bullish· Jul 10

$FBRX has shown significant growth, surging 14.3% on favorable sector trends and strong demand, with the share price rising to $41.95.
The company's Phase 1b data for vitiligo treatment showed a benefit over placebo and favorable safety, with a worldwide treatment area of $1.5 billion.
$FBRX has broken out of a long accumulation phase, reclaiming its 20D and 50D moving averages with strong volume, and a hold above $40 could signal a move towards $50.

Bearish· Jul 10

The company may be fiscally irresponsible if it doesn't drop an offering to monetize its 78% gains.
The stock's recent price increase may be unsustainable, especially considering the expensive and long Phase 3 trial still to come.
The stock's rapid price appreciation may be a sign of a potential rug pull, with some investors already selling out and others expecting a collapse.

Generated by AI

Topics

Of the messages about FBRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	84.41%
Technical Analysis	0%	0%	0%	14.35%
Controversies	0%	0%	0%	0.15%
Analysts	0%	0%	0%	1.08%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Analysts· Sep 3

B. Riley Securities downgraded Forte Biosciences (FBRX) to Neutral from Buy with a $3 price target.
Analysts are divided on FBRX, with some firms downgrading and others maintaining a Buy rating, and price targets ranging from $3 to $90.
Chardan Capital and Truist Securities downgraded FBRX to Sell and Hold, respectively, with price targets of $4.

Announcements· Jul 27

Argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion, with the transaction expected to close in Q3 2026.
The acquisition price reflects an approximately 86% premium to Forte Biosciences' volume-weighted average price since reporting positive Phase 1b data in vitiligo.
The deal is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Forte Biosciences and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Technical Analysis· Apr 9

$FBRX has broken through resistance at $29.13, with a high-volume surge of +28.47% confirming institutional interest and projecting a technical target of $45.85.
The stock's momentum is accelerating, with a +29.16% surge to $33.93, following the clearance of major resistance at $29.20 on massive volume (1.82M).
The $150M public offering is providing a fundamental catalyst for the momentum surge, with the stock targeting $45.43 and potentially reaching $46.24 or $46.46 based on measured move projections.

Generated by AI

Community

Of the messages about FBRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	71.43%	84.42%	83.52%	33.41%
Newcomers	28.57%	15.58%	16.48%	66.59%

Regulars· Jul 27

Argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2B, and the acquisition is expected to close in Q3 2026.
The price reflects an about 86% premium to Forte's volume-weighted average price since reporting Phase 1b data in vitiligo on July 9.
The acquisition will be executed through a tender offer followed by a merger, with the tender offer having not yet commenced.

Newcomers· Jul 28

Forte Biosciences, Inc. has been acquired by argenx SE in an all-cash deal valued at approximately $2.2 billion, with argenx paying $77 per share.
The acquisition comes after positive early-stage data for Forte's lead drug FB102, which has driven a 560% stock rally over the last 12 months.
The deal validates Forte's pipeline potential in a hot M&A biotech environment, with argenx acquiring Forte's autoimmune candidate for vitiligo and celiac disease.

Generated by AI

argenx (ENXTBR:ARGX) has completed its acquisition of Forte Biosciences, adding antibody candidate FB102 to its immunology pipeline. The transaction supports argenx's Vision 2030 plan to broaden its presence in autoimmune disease treatment. FB102 is expected to be integrated into argenx's existing research and development programs focused on immunology. For readers who want more ideas in advanced immunology and related technologies, the next step is to explore 134 healthcare AI...

1mo agoYahoo Finance

argenx completes acquisition of Forte Biosciences for $77 per share

1mo agoInvesting.com

argenx Completes Acquisition of Forte Biosciences, Inc.

Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline

1mo agoBarchart.com

Also Discussed

Investors talking about FBRX also mention

#	Name	Attention
1	Sol-Gel Technologies Ltd.SLGL	0%0
2	Gyre Therapeutics Inc.GYRE	0%0
3	Evelo Biosciences Inc.EVLO	0%0
4	Fortrea Holdings Inc.FTRE	0%0
5	Atea Pharmaceuticals, Inc.AVIR	0%0
6	ETWO - E2open Parent Holdings, Inc.	——
7	Vestis CorporationVSTS	0%new
8	Dianthus Therapeutics Inc.DNTH	0%0
9	BeyondSpring Inc.BYSI	0%0
10	Integra LifeSciences Holdings CorporationIART	0%0

Forte Biosciences, Inc.

Healthcare
Biotechnology

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and autoimmune-related diseases. Its current lead product candidate is FB102, a proprietary anti-CD122 monoclonal antibody being advanced for a range of immune-mediated conditions, including vitiligo, alopecia areata, celiac disease, graft-versus-host disease, and type 1 diabetes. The company’s work centers on targeted immunology research and drug development, with an emphasis on addressing diseases driven by abnormal immune activity. Based in Dallas, Texas, Forte Biosciences operates within the biotechnology sector and plays a role in advancing potential treatments for dermatology and broader autoimmune medicine.

Website

Location

3060 Pegasus Park Drive

Dallas, TX, 75247

United States

Social

What share of all stock conversation is about FBRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 28

Forte Biosciences (FBRX) is being acquired by argenx for approximately $2.2 billion, or $77 per share in cash, an 86% premium over the company's average stock price since its strong rally.
The acquisition of FBRX is valued at $2.2 billion, with Forte's autoimmune candidate FB102, for vitiligo and celiac disease, being the prize.
FBRX surged 40% after the acquisition announcement, with some analysts considering the deal a strong validation of the company's pipeline potential in a hot M&A biotech environment.

Generated by AI

Sentiment

Of the messages about FBRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +13.33	83.79% +2.65
Bearish	—	—	0% -13.33	16.21% -2.65

Bullish· Jul 10

$FBRX has shown significant growth, surging 14.3% on favorable sector trends and strong demand, with the share price rising to $41.95.
The company's Phase 1b data for vitiligo treatment showed a benefit over placebo and favorable safety, with a worldwide treatment area of $1.5 billion.
$FBRX has broken out of a long accumulation phase, reclaiming its 20D and 50D moving averages with strong volume, and a hold above $40 could signal a move towards $50.

Bearish· Jul 10

The company may be fiscally irresponsible if it doesn't drop an offering to monetize its 78% gains.
The stock's recent price increase may be unsustainable, especially considering the expensive and long Phase 3 trial still to come.
The stock's rapid price appreciation may be a sign of a potential rug pull, with some investors already selling out and others expecting a collapse.

Generated by AI

Topics

Of the messages about FBRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	84.41%
Technical Analysis	0%	0%	0%	14.35%
Controversies	0%	0%	0%	0.15%
Analysts	0%	0%	0%	1.08%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%

Analysts· Sep 3

B. Riley Securities downgraded Forte Biosciences (FBRX) to Neutral from Buy with a $3 price target.
Analysts are divided on FBRX, with some firms downgrading and others maintaining a Buy rating, and price targets ranging from $3 to $90.
Chardan Capital and Truist Securities downgraded FBRX to Sell and Hold, respectively, with price targets of $4.

Announcements· Jul 27

Argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion, with the transaction expected to close in Q3 2026.
The acquisition price reflects an approximately 86% premium to Forte Biosciences' volume-weighted average price since reporting positive Phase 1b data in vitiligo.
The deal is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Forte Biosciences and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Technical Analysis· Apr 9

$FBRX has broken through resistance at $29.13, with a high-volume surge of +28.47% confirming institutional interest and projecting a technical target of $45.85.
The stock's momentum is accelerating, with a +29.16% surge to $33.93, following the clearance of major resistance at $29.20 on massive volume (1.82M).
The $150M public offering is providing a fundamental catalyst for the momentum surge, with the stock targeting $45.43 and potentially reaching $46.24 or $46.46 based on measured move projections.

Generated by AI

Community

Of the messages about FBRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	71.43%	84.42%	83.52%	33.41%
Newcomers	28.57%	15.58%	16.48%	66.59%

Regulars· Jul 27

Argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2B, and the acquisition is expected to close in Q3 2026.
The price reflects an about 86% premium to Forte's volume-weighted average price since reporting Phase 1b data in vitiligo on July 9.
The acquisition will be executed through a tender offer followed by a merger, with the tender offer having not yet commenced.

Newcomers· Jul 28

Forte Biosciences, Inc. has been acquired by argenx SE in an all-cash deal valued at approximately $2.2 billion, with argenx paying $77 per share.
The acquisition comes after positive early-stage data for Forte's lead drug FB102, which has driven a 560% stock rally over the last 12 months.
The deal validates Forte's pipeline potential in a hot M&A biotech environment, with argenx acquiring Forte's autoimmune candidate for vitiligo and celiac disease.

Generated by AI

Forte Biosciences

Social

Jul 28

Bullish· Jul 10

Bearish· Jul 10

Analysts· Sep 3

Announcements· Jul 27

Technical Analysis· Apr 9

Regulars· Jul 27

Newcomers· Jul 28

Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition

argenx completes acquisition of Forte Biosciences for $77 per share

argenx Completes Acquisition of Forte Biosciences, Inc.

Argenx Completes Acquisition of Forte Biosciences

Forte Biosciences earnings on deck as argenx deal looms

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Also Discussed

Forte Biosciences, Inc.

Company Information

Location

Argenx (ENXTBR:ARGX) Completes Forte Biosciences Acquisition

argenx completes acquisition of Forte Biosciences for $77 per share

argenx Completes Acquisition of Forte Biosciences, Inc.

Argenx Completes Acquisition of Forte Biosciences

Forte Biosciences earnings on deck as argenx deal looms

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Also Discussed

Social

Jul 28

Bullish· Jul 10

Bearish· Jul 10

Analysts· Sep 3

Announcements· Jul 27

Technical Analysis· Apr 9

Regulars· Jul 27

Newcomers· Jul 28